[HTML][HTML] Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance
DLH Chan, N Pavlakis, GP Schembri, EJ Bernard… - Theranostics, 2017 - ncbi.nlm.nih.gov
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
DL Chan, N Pavlakis, GP Schembri… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
[PDF][PDF] Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
DLH Chan, N Pavlakis, GP Schembri, EJ Bernard… - researchgate.net
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
DL Chan, N Pavlakis, GP Schembri, EJ Bernard… - Theranostics, 2017 - europepmc.org
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance
DLH Chan, N Pavlakis, GP Schembri… - …, 2017 - researchers.mq.edu.au
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
[PDF][PDF] Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
DLH Chan, N Pavlakis, GP Schembri, EJ Bernard… - pdfs.semanticscholar.org
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
[PDF][PDF] Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
DLH Chan, N Pavlakis, GP Schembri, EJ Bernard… - academia.edu
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
DL Chan, N Pavlakis, GP Schembri, EJ Bernard… - Theranostics, 2017 - hero.epa.gov
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance
DL Chan, N Pavlakis, GP Schembri, EJ Bernard… - 2017 - dro.deakin.edu.au
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …
[引用][C] Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
DLH Chan, N Pavlakis, GP Schembri, EJ Bernard… - Theranostics, 2017 - cir.nii.ac.jp
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours:
Proposal for a Novel Grading Scheme with Prognostic Significance | CiNii Research CiNii 国立 …
Proposal for a Novel Grading Scheme with Prognostic Significance | CiNii Research CiNii 国立 …